Drug Details
General Information of the Drug (ID: DR7530) | ||||
---|---|---|---|---|
Name |
Fluvastatin
|
|||
Synonyms |
fluvastatin; 93957-54-1; (3R,5S)-fluvastatin; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (+)-(3R,5S)-fluvastatin; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; CHEBI:38565; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,E)-7-(3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; CHEMBL1078; Fluvastatin & Primycin; (-)-fluvastatin; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-isopropyl-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; PubChem10727; DSSTox_CID_636; Prestwick2_000859; SCHEMBL2846; DSSTox_RID_75707; DSSTox_GSID_20636; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; SCHEMBL556754; GTPL2951; DTXSID2020636; BDBM86704; CHEBI:93160; HMS2089P06; HMS3259J15; Pharmakon1600-01504911; ACT03305; ZINC1886617; Tox21_302765; DL-108; HY-14664B; NSC758896; CCG-213323; NC00659; NSC-758896; NCGC00256490-01; CAS-93957-54-1; CAS_93957-54-1; CS-0019897; EN300-51915; W-5176; 957F541; Q417942; SR-05000001489-1; BRD-K66296774-001-02-0; UNII-4L066368AS component FJLGEFLZQAZZCD-MCBHFWOFSA-N; (E)-(3R,5S)-7-[3-(4-Fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)-; Fluvastatin sodium L1483
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Hypertriglyceridaemia [ICD-11: 5C80] | Approved | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C24H26FNO4
|
|||
PubChem CID | ||||
Canonical SMILES |
CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F
|
|||
InChI |
1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1
|
|||
InChIKey |
FJLGEFLZQAZZCD-MCBHFWOFSA-N
|
|||
CAS Number |
CAS 93957-54-1
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Metformin | Galega officinalis | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vivo Model | Clinical trial | |||||
Experimental
Result(s) |
Use of statin and metformin provides a synergistic improvement in gastrointestinal malignancies outcomes. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | HMG-CoA reductase (HMGCR) | Molecule Info | [3] | |
BioCyc | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | Click to Show/Hide | ||
2 | Superpathway of cholesterol biosynthesis | |||
3 | Mevalonate pathway | |||
KEGG Pathway | Terpenoid backbone biosynthesis | Click to Show/Hide | ||
2 | Metabolic pathways | |||
3 | Biosynthesis of antibiotics | |||
4 | AMPK signaling pathway | |||
5 | Bile secretion | |||
NetPath Pathway | IL5 Signaling Pathway | Click to Show/Hide | ||
2 | TGF_beta_Receptor Signaling Pathway | |||
3 | TSH Signaling Pathway | |||
Panther Pathway | Cholesterol biosynthesis | Click to Show/Hide | ||
Pathwhiz Pathway | Steroid Biosynthesis | Click to Show/Hide | ||
WikiPathways | Statin Pathway | Click to Show/Hide | ||
2 | Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||
3 | Activation of Gene Expression by SREBP (SREBF) | |||
4 | SREBF and miR33 in cholesterol and lipid homeostasis | |||
5 | Integrated Breast Cancer Pathway | |||
6 | SREBP signalling | |||
7 | Cholesterol Biosynthesis |
